Abstract
Carbapenems are the most appropriate antimicrobials for empiric and pathogen-directed monotherapy in most severe and life-threatening infections in pediatric patients. It can be explained by broadest spectrum of activity, including multidrug resistant pathogens, stability against b-lactamases, and low incidence of adverse drug reactions. In addition, use of carbapenems as monotherapy may reduce risk of adverse drug interactions. Both many clinical trials and extensive clinical use in children with severe infections (bacterial meningitis, pneumonia, sepsis, cystic fibrosis, intra-abdominal infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, febrile neutropenia) demonstrated high efficacy and favorable safety profile of meropenem.
-
1.
Bradley J.S. Selecting therapy for serious infections in children:maximizing safety and efficacy. Diagn Microbiol Infect Dis 1998; 31:405-10.
-
2.
Reed M.D., Goldfarb J., Blumer J.L. Anti-infective therapy. In:Jensen HB, Baltimore RS, editors. The Practice of Pediatric Infectious Diseases. East Norwalk:Appleton & Lange, 1995:177-273.
-
3.
Blumer J.L. Carbapenems in paediatrics. Scand J Infect Dis 1995; (Suppl.) 96:38-44.
-
4.
Barrier S.L. Selection of antimicrobial regimens. In: DiPiro J.T., Talbert R.L., Hayes P.E., et al., editors. Pharmacotherapy. A Pathophysiologic Approach. 2nd ed. East Norwalk:Appleton & Lange, 1993:1508-23.
-
5.
Snedden S., Rudoy R., Arrieta A. Meropenem vs cefotaxime-based therapy for the Initial treatment of infants and children hospitalized with non-CNS infections. Clin Drug Invest 1999; 17(1):9-20.
-
6.
Neu H.C. Why carbapenems? Curr Opin Infect Dis 1994; 7 (Suppl. 1):S3-S10.
-
7.
Nicolau D.P. Carbapenems:a potent class of antibiotics. Expert Opin Pharmacother, 2008; 9(1):23-37.
-
8.
Ayalew K., Nambiar S., Yasinskaya Y., et al., Carbapenems in pediatrics. Ther Drug Monit 2003; 25(5):593-9.
-
9.
Bradley J.S., Garau J., Lode H., et al., Carbapenems in clinical practice:a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11(2):93-100.
-
10.
Paul, M., et al., Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients:systematic review and metaanalysis of randomised trials. BMJ 2004; 328:668.
-
11.
USP DI. Drug Information for health care professional. 20th Ed. Micromedex Inc., 2000.
-
12.
Меропенем. Типовая клинико-фармакологическая статья. Available from: http://www.regmed.ru/
-
13.
Имипенем/циластатин. Типовая клинико-фармакологическая статья. Available from: http://www.regmed.ru/
-
14.
Эртапенем. Типовая клинико-фармакологическая статья. Available from:http://www.regmed.ru/
-
15.
Zhanel G.G., Wiebe R., Dilay L., et al. Comparative review of the carbapenems. Drugs, 2007; 67 (7):1027-52.
-
16.
Baldwin C.M., Lyseng-Williamson K.A., Keam S.J. Meropenem :a review of its use in the treatment of serious bacterial infections. Drugs 2008; 68:803-38.
-
17.
Shah P.M. Parenteral carbapenems. Clin Microbiol Infect 2008; 14 (Suppl 1):175-80.
-
18.
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition, ed. L.L. Brunton, et al. 2006.
-
19.
Joseph J., Rodvold K.A. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother 2008; 9(4):561-75.
-
20.
Яковлев С.В. Устойчивость Pseudomonas aeruginosa к карбапенемам:уроки исследования MYSTIC. Фарматека 2007; (8-9):67-70.
-
21.
Turner P.J. Meropenem activity against European isolates:report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008; 60 (2):185-92.
-
22.
Merrem [package insert]. Wilmington, DE:AstraZeneca Corp; 2007.
-
23.
Hurst M., Lamb H.M. Meropenem: a review of its use in patients in intensive care. Drugs 2000; 59:653-80.
-
24.
Tunkel A.R., Hartman B.J., Kaplan S.L., et al., Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39(9):1267-84.
-
25.
Odio C.M., Puig J.R., Feris J.M., et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 1999; 18(7):581-90.
-
26.
Klugman K.P., Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995; 39(5):1140-6.
-
27.
Bradley J.S., Faulkner K.L., Klugman K.P. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients. Pediatr Infect Dis J 1996; 15:749-57.
-
28.
Cometta A., Viscoli C., Castagnola E., et al., Empirical treatment of fever in neutropenic children:the role of the carbapenems. International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer and the Gimema Infection Program. Pediatr Infect Dis J 1996; 15(8):744-8.
-
29.
Fleischhack, G., Hartmann C., Simon A., et al, Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 2001; 47(6):841-53.
-
30.
Hung K.C., Chiu H.H., Tseng Y.C., Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. J Microbiol Immunol Infect 2003; 36:254-9.
-
31.
Agaoglu L., Devecioglu O., Anak S., et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001; 13:281-7.
-
32.
Düzova A., Kutluk T., Kanra G., et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr 2001; 43:105-9.
-
33.
Kutluk T., Kurne O., Akyüz C., et al. Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr Blood Cancer 2004; 42:284-6.
-
34.
Aksoylar S., Cetingul N., Kantar M., et al. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol 2004; 21:115-23.
-
35.
Paul M., Yahav D., Fraser A., et al. Empirical antibiotic monotherapy for febrile neutropenia:systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57:176-89.
-
36.
Чучалин А.Г., Страчунский Л.С., Козлов Р.С., с соавт. Нозокомиальная пневмония у взрослых:практические рекомендации по диагностике, лечению и профилактике (Пособие для врачей). Клин микробиол антимикроб химиотер 2005; 1:4-31.
-
37.
Principi N., Marchisio P. Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group. J Chemother 1998; 10:108- 13.
-
38.
Byrne S., Maddison J., Connor P., et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother 1995; 36 (Suppl A):135-43.
-
39.
Blumer J.L., Saiman L., Konstan M.W., et al. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005; 128:2336-46.
-
40.
Latzin P., Fehling M., Bauernfeind A., et al. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros 2008; 7:142-6.
-
41.
Arrieta A. Use of meropenem in the treatment of serious infections in children:Review of the current literature. Clin Infect Dis 1997; 24(Suppl. 2):S207-12.
-
42.
Martinova J., de Groot R., Chladek J., et al. Meropenem pharmacokinetics in pre-term and full-term neonates. In: Program and Abstracts of the 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna 1995, р. 133.
-
43.
Parker E.M., Hutchison M., Blumer J.L. The pharmacokinetics of meropenem in infants and children:A population analysis. J Antimicrob Chem 1995; 36 (Suppl. A):63-71.
-
44.
van Enk J.G., Touw D.J., Lafeber H.N. Pharmacokinetics of meropenem in preterm neonates. Ther Drug Monit 2001; 23:198-201.
-
45.
Motohiro T., Oki S., Tsumura N., et al. Basic and clinical study of meropenem in pediatric field. Jpn J Antibiot 1992; 45:1356-84.
-
46.
Koksal N., Hacimustafaoglu M., Bagci S., et al. Meropenem in neonatal severe infections due to multiresistant gramnegative bacteria. Indian J Pediatr 2001; 68:15-9.
-
47.
De Cunto A., Tana M., Vendettuoli V., et al. Use of Meropenem in preterm newborns. Survey of the literature and case series. Minerva Pediatr 2007; 59:755-60.
-
48.
Яцык Г.В. Использование меропенема в лечении тяжелых инфекций у новорожденных детей. Антибиотики и химиотерапия 1998; 43(1). Available from:http://medi.ru/doc/091107.htm.
-
49.
Бирюков А.В., Белобородова Н.В., Моисеев Д.Б. Опыт использования меропенема в терапии тяжелых бактериальных инфекций у новорожденных и детей. Вестник интенсивной терапии 1998; 2. Available from: http://medi.ru/doc/8180206.htm.
-
50.
Norrby S.R., Gildon K.M. Safety profile of meropenem:a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1999; 31:3-10.
-
51.
Linden P. Safety profile of meropenem:an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007; 30:657-68.
-
52.
Wong V.K., Wright H.T. Jr., Ross L.A., et al. Imipenem/ cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991; 10:122-5.
-
53.
Eng R.H., Munsif A.N., Yangco B.G., et al. Seizure propensity of imipenem. Arch Intern Med 1989; 149:1881- 3.
-
54.
Saxon A., Adelman D.C., Patel A., et al. Imipenem crossreactivity with penicillin in humans. J Allergy Clin Immunol 1988; 82:213-7.
-
55.
Prescott Jr. W.A., Kusmierski K.A. Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy. Pharmacotherapy 2007; 27:137-42.
-
56.
Schuler D., Safety and efficacy of meropenem in hospitalised children:randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. J Antimicrob Chemother 1995; 36 (Suppl A):99-108.
-
57.
Atanasković-Marković M., Gaeta F., Medjo B., et al. Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. Allergy 2008; 63:237-40.